Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids
The results identify several novel loci associated with plasma lipids that are also associated with CAD and provide the foundation to develop a broader biological understanding of lipoprotein metabolism and to identify new therapeutic opportunities for the prevention of CAD.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
Clinicians are updated on the increasingly crucial role of triglycerides in the evaluation and management of CVD risk and highlight approaches aimed at minimizing the adverse public health–related consequences associated with hypertriglyceridemic states.
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.
The term "vulnerable patient" may be more appropriate and is proposed now for the identification of subjects with high likelihood of developing cardiac events in the near future and a quantitative method for cumulative risk assessment of vulnerable patients needs to be developed.
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than amongThose who received placebo.
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.
Results of logistic regression analyses indicated that the relationship of ICAM-1 and E-selectin with CHD and CAA was independent of other known CHD risk factors and was most pronounced in the highest quartile.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
- M. Sabatine, R. Giugliano, E. Stein
- Medicine, BiologyThe New England journal of medicine
- 1 October 2015
During approximately 1 year of therapy, the use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels and reduced the incidence of cardiovascular events in a prespecified but exploratory analysis.
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study.
Individuals without diabetes or CVD, but with the metabolic syndrome, were at increased risk for long-term cardiovascular outcomes, although statistical models suggested that most of that risk was accounted for by the FRS.